Merck KGaA (MRK) - Financial and Strategic SWOT Analysis Review

  • ID: 1292018
  • SWOT Analysis
  • 77 pages
  • GlobalData
  • Merck Group
1 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • BASF SE
  • Eli Lilly and Co
  • GlaxoSmithKline Plc
  • NewLink Genetics Corp
  • Novartis AG
  • MORE
Merck KGaA (MRK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Merck KGaA (Merck), a subsidiary of E. Merck KG, is a pharmaceutical and chemical company. It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis, and infertility and over-the-counter products for colds and pain; and develops liquid crystal mixtures, OLED materials and cosmetic active ingredients. The company also provides a wide range of products including lab water systems to gene editing tools, cell lines, antibodies and end-to-end systems. Merck serves healthcare, performance materials and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa. Merck is headquartered in Darmstadt, Hesse, Germany.

Merck KGaA Key Recent Developments

Apr 05, 2018: Merck and Schneider Electric Sign MoU to Advance China’s Biopharmaceutical Industry
Apr 04, 2018: MilliporeSigma to Launch New Flow Cytometer, Host CellStream Workshop at CYTO 2018
Mar 29, 2018: Merck Showcases New Innovations at INTERPHEX 2018
Mar 26, 2018: ITRI Collaborates with Merck to Enhance New Drug Manufacturing
Mar 20, 2018: Merck KGaA, Darmstadt, Germany to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on 22nd March 2018

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • BASF SE
  • Eli Lilly and Co
  • GlaxoSmithKline Plc
  • NewLink Genetics Corp
  • Novartis AG
  • MORE
Section 1 - About the Company
  • Merck KGaA - Key Facts
  • Merck KGaA - Key Employees
  • Merck KGaA - Key Employee Biographies
  • Merck KGaA - Key Operational Employees
  • Merck KGaA - Major Products and Services
  • Merck KGaA - History
  • Merck KGaA - Company Statement
  • Merck KGaA - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Merck KGaA - Business Description
  • Business Segment: Healthcare
  • Overview
  • Performance
  • Business Segment: Life ­Science
  • Performance
  • Business Segment: Life Science
  • Overview
  • Key Stats
  • Business Segment: Performance Materials
  • Overview
  • Performance
  • Geographical Segment: Asia Pacific
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Latin America
  • Performance
  • Geographical Segment: Middle East and Africa
  • Performance
  • Geographical Segment: North America
  • Performance
  • R&D Overview
  • Merck KGaA - Corporate Strategy
  • Merck KGaA - SWOT Analysis
  • SWOT Analysis - Overview
  • Merck KGaA - Strengths
  • Merck KGaA - Weaknesses
  • Merck KGaA - Opportunities
  • Merck KGaA - Threats
  • Merck KGaA - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Merck KGaA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Merck KGaA, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 05, 2018: Merck and Schneider Electric Sign MoU to Advance China’s Biopharmaceutical Industry
  • Apr 04, 2018: MilliporeSigma to Launch New Flow Cytometer, Host CellStream Workshop at CYTO 2018
  • Mar 29, 2018: Merck Showcases New Innovations at INTERPHEX 2018
  • Mar 26, 2018: ITRI Collaborates with Merck to Enhance New Drug Manufacturing
  • Mar 20, 2018: Merck KGaA, Darmstadt, Germany to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on 22nd March 2018
  • Mar 19, 2018: The Pistoia Alliance Calls for Greater Life Sciences Collaboration to Build the ‘Lab of the Future’
  • Mar 01, 2018: Merck to Present New Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at CROI 2018
  • Feb 23, 2018: Fish & Richardson Wipes Out $2.5 Billion Patent Verdict Against Gilead Sciences on JMOL
  • Feb 21, 2018: Merck Invests Additional €40 Million to Enhance Manufacturing and Distribution in Asia
  • Feb 20, 2018: Merck Receives Two More Patents for CRISPR Technology
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Merck KGaA, Key Facts
  • Merck KGaA, Key Employees
  • Merck KGaA, Key Employee Biographies
  • Merck KGaA, Key Operational Employees
  • Merck KGaA, Major Products and Services
  • Merck KGaA, History
  • Merck KGaA, Subsidiaries
  • Merck KGaA, Key Competitors
  • Merck KGaA, Ratios based on current share price
  • Merck KGaA, Annual Ratios
  • Merck KGaA, Annual Ratios
  • Merck KGaA, Annual Ratios
  • Merck KGaA, Interim Ratios
  • Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Merck KGaA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Merck KGaA, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Merck KGaA, Performance Chart (2013 - 2017)
  • Merck KGaA, Ratio Charts
  • Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Merck KGaA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Sanofi
  • Novartis AG
  • NewLink Genetics Corp
  • GlaxoSmithKline Plc
  • Eli Lilly and Co
  • BASF SE
  • AstraZeneca Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll